Osivax's flu vaccine OVX836 fails Phase 2b trial, company pivots to combination approach
French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.
